Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2026.02.20

Sai Life Sciences to recruit 700+ professionals in FY27

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and manufacturing organizations (CRDMOs), today announced plans to hire 700+ scientific, technical, and management professionals during 2026–27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services.
The recruitment will span roles across medicinal chemistry, biology, DMPK, process and analytical development, formulation development, process engineering, technology transfer, quality, peptides, business development, program management, and manufacturing, among others.
A specific area of focus through this recruitment drive will be on attracting high-calibre scientists from leading institutions in India and globally, reflecting the increasing complexity of programs being entrusted to Sai Life Sciences and the higher scientific expectations placed on Indian CRDMOs by global innovator companies.
Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “We are at an inflection point for the Indian CRDMO industry. Global supply-chain rebalancing, the need for resilient development and manufacturing partners, and the rising sophistication of outsourced science are converging in India’s favour. Demand for high-quality, integrated partners is already visible, and this expansion is about preparing ourselves to serve that demand at scale — with the right infrastructure, strong digital and quality systems, and deep scientific capability.”
Krishna added, “For scientists, this is a genuinely exciting moment. They have the opportunity to work on globally relevant, high-impact programs while being based in India. We believe this phase of growth creates a compelling opportunity for Indian scientists anywhere in the world to consider building the next chapter of their careers here—without compromising on scientific rigor, exposure, or the quality of work.”
The new roles will support growing activity in areas such as complex small-molecule synthesis, high-throughput experimentation, data-enabled drug discovery, and late-stage CMC and commercial manufacturing scale-up.
As part of its talent strategy, Sai Life Sciences has launched a global alumni engagement platform and is strengthening learning, leadership development, and internal mobility programs to support long-term career growth.
Sai Life Sciences operates across India, the UK, and the US, serving global pharmaceutical and biotechnology companies. Its Manchester site focuses on process R&D, while its Boston Biology facility supports early discovery collaborations and client engagement. The majority of new roles will be based in Hyderabad, home to the company’s largest integrated R&D campus. With more than 3,400 scientists and professionals currently on board, the planned hiring reflects the company’s continued growth and its expanding role as a global CRDMO partner.

Share article

More News

2026.02.06

Sai Life Sciences Limited delivers robust performance in 9MFY26

Revenue up by 43%; EBITDA up by 79%; Net Profit up by 199% Hyderabad, February 05, 2026: Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), one of India’s fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO) announced its financial results for the third quarter and nine months ended December 2025. Financial Performance: Particulars […]
Read more

2026.01.28

Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site

Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a strategic collaboration that establishes Sai’s Boston laboratory as a co-marketed US execution and demonstration hub for the Mabtech EYRA™ platform. Under this collaboration, Mabtech and Sai will […]
Read more

2026.01.12

Sai Life Sciences laboratories achieve Green Lab Certification

Sai Life Sciences has achieved Green Lab Certification for two PR&D laboratories and two Medicinal Chemistry laboratories under the My Green Lab (MGL) framework, with a compliance score of over 98%.The certification reflects the company’s systematic efforts to integrate sustainability into daily laboratory operations, with measurable reductions in energy consumption, water usage, waste generation, and […]
Read more

2025.12.19

Sai Life Sciences Releases Sustainability Report 2025

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest-growing Contract Research, Development, and Manufacturing Organizations (CRDMO), today announced the release of its Sustainability Report for 2024–25. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 and the Sustainability Accounting Standards Board (SASB) standards, this sixth edition is presented under the […]
Read more

2025.12.15

Pushing Boundaries in Organic Chemistry: IISc Prof. Santanu Mukherjee at Sai Life Sciences

As part of Sai Life Sciences’ ongoing initiative to foster meaningful scientific engagement through interactions with distinguished researchers, Prof. Santanu Mukherjee, Professor in the Department of Organic Chemistry at IISc Bangalore, visited our Integrated R&D campus for a full-day programme of knowledge exchange. He delivered an insightful masterclass on his group’s work in enantioselective desymmetrization—a […]
Read more